Exploring GPRC5D as an Important Target for Multiple Myeloma

Publication
Article
ONCOLOGY® CompanionONCOLOGY® Companion, Volume 38, Supplement 9
Volume 38
Issue 9
Pages: 3

Experts highlighted the use of GPRC5D therapy in patients with multiple myeloma.

Meet the experts

Meet the experts

A recent Training Academy highlighted the use of GPRC5D therapy in patients with multiple myeloma. The most common and only approved option is talquetamab-tgvs (Talvey). The panel highlighted the treatment in the phase 1/2 MonumenTAL-1 trial (NCT03399799; NCT04634552).

Using, Treating, and Sequencing GPRC5D Therapy

  • An important target because there needs to be a range of options developed to treat multiple myeloma.
    • This can be used prior to a B-cell maturation antigen (BCMA).
  • Can be considered to be used as a bridge to a BCMA or chimeric antigen receptor T-cell therapy.
  • GPRC5D is more commonly expressed in malignant plasma vs normal.
  • Combination therapies may produce higher efficacy rates than these monotherapies.
  • Talquetamab was assessed in the phase 1/2 MonumenTAL-3 trial (NCT05455320).
  • The most common toxicities include oral and skin.
    • Not as severe as with bispecific antibodies.
    • Hypothesized, as this is given one treatment at a time vs continuous bispecific use.
  • Dose de-escalation can be helpful to manage.
    • Monthly treatment may be an option to help lessen or avoid dysgeusia.
  • Talquetamab has not shown adverse effects (AEs) related to cardiac issues, pulmonary issues, renal issues, or neuropathy.
  • AEs typically happen at first onset and then lessen as the disease becomes better controlled.
  • As a GPRC5D target, there is less infectious toxicity involved.
    • Intravenous immunoglobulin supplementation is not needed as much.
Recent Videos
4 experts in this video
4 experts in this video
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
Although a similar proportion achieved MRD negativity at the 10 to the –6 power, not enough studies have analyzed MRD at this level for multiple myeloma.
Unique toxicities presented with talquetamab tend to get progressively better as the treatment course continues, according to Prerna Mewawalla, MD.
Related Content